Polymorphisms in the genes encoding interferon-gamma and interferon-gamma receptors in multiple sclerosis.

Genome screens suggest that several genes, each contributing to a small extent, are involved in multiple sclerosis (MS) susceptibility. Simultaneous analysis of related genes may improve the power to detect such small effects. Interferon-gamma (IFN-gamma), mediating its effects through the IFN-gamma receptor, is a pleiotropic, pro-inflammatory cytokine for which a detrimental effect on the course of MS has been reported. The role of IFN-gamma receptor 1 (IFNGR1) and IFN-gamma receptor 2 (IFNGR2) gene polymorphisms has not been studied in MS, and, for the IFNG gene polymorphism there is only one previous study, which incorporates clinical, but not imaging, data. The aim of this study was to investigate whether polymorphisms in the IFNG and IFNGR1 and IFNGR2 genes are associated with susceptibility to MS, or disease characteristics, as defined by clinical and imaging criteria. Genotypes for IFNG, IFNGR1 and IFNGR2 were determined in 509 patients with MS and in 193 healthy controls. Patient files were reviewed for disease course, age at onset of disease, and rate of progression. Serial magnetic resonance imaging (MRI) data were available for 107 patients. No significant differences in the distribution of IFNG, IFNGR1 and IFNGR2 genotype and allele frequencies were found between patients and controls. A progressive, as opposed to a relapsing, onset was significantly more frequent in carriers of the IFNGR2 allele Arg64 (P = 0.028). Moreover, IFNGR2 allele Arg64 carriers had a lower black hole ratio than non-carriers (P = 0.016). No other associations with clinical parameters, such as age at onset or rate of progression, or with imaging parameters, were observed. The IFNG intron 1 gene polymorphism studied is unlikely to play a major role in MS susceptibility or disease course. The IFNGR1 and IFNGR2 gene polymorphisms studied do not exert an important influence on MS susceptibility, but allele IFNGR2*Arg64 may be associated with a progressive disease onset.

[1]  Ansgar Steland,et al.  Multilocus statistics to uncover epistasis and heterogeneity in complex diseases: revisiting a set of multiple sclerosis data , 2003, European Journal of Human Genetics.

[2]  M. Filippi,et al.  Inflammation in multiple sclerosis: the good, the bad, and the complex , 2002, The Lancet Neurology.

[3]  M. Kaps,et al.  Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis , 2002, Acta neurologica Scandinavica.

[4]  D. Parzy,et al.  Description of three new polymorphisms in the intronic and 3′UTR regions of the human interferon gamma gene , 2002, Genes and Immunity.

[5]  B. Weinshenker,et al.  Identifying disease modifying genes in multiple sclerosis , 2002, Journal of Neuroimmunology.

[6]  A. Cambon-Thomsen,et al.  Interferon gamma gene polymorphism and susceptibility to, and severity of, rheumatoid arthritis , 2001, The Lancet.

[7]  F Barkhof,et al.  Optimizing the association between disability and biological markers in MS , 2001, Neurology.

[8]  H. Harbo,et al.  Analysis of an interferon-γ gene dinucleotide-repeat polymorphism in Nordic multiple sclerosis patients , 2001 .

[9]  D. Lacaille,et al.  Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis , 2000, The Lancet.

[10]  A. Stevens,et al.  A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. , 2000, Human immunology.

[11]  R. Pukrop,et al.  Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients , 2000, Multiple sclerosis.

[12]  M. Babron,et al.  Cytokines in genetic susceptibility to multiple sclerosis: a candidate gene approach , 2000, Journal of Neuroimmunology.

[13]  R. Döffinger,et al.  Nonpathogenic common variants of IFNGR1 and IFNGR2 in association with total serum IgE levels. , 1999, Biochemical and biophysical research communications.

[14]  A. Goris,et al.  Analysis of an IFN-gamma gene (IFNG) polymorphism in multiple sclerosis in Europe: effect of population structure on association with disease. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[15]  V. Giedraitis,et al.  Mutation screening of the interferon-gamma gene as a candidate gene for multiple sclerosis. , 1999, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[16]  H. Niiro,et al.  The combination of polymorphisms within interferon‐γ receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus , 1999, FEBS letters.

[17]  H. Niiro,et al.  Association of the interferon-γ receptor variant (Val14Met) with systemic lupus erythematosus , 1999, Immunogenetics.

[18]  A. Hajeer,et al.  In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. , 1999, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[19]  A. Goris,et al.  Interferon‐γ gene polymorphism–associated risk for multiple sclerosis in sardinia , 1998, Annals of neurology.

[20]  D. Comings.  Why different rules are required for polygenic inheritance: lessons from studies of the DRD2 gene. , 1998, Alcohol.

[21]  Chun Xu,et al.  Linkage and association analysis of genes encoding cytokines and myelin proteins in multiple sclerosis , 1998, Journal of Neuroimmunology.

[22]  F. Belardelli,et al.  IFN-γ Expression in Macrophages and Its Possible Biological Significance , 1998 .

[23]  H. Link.  The cytokine storm in multiple sclerosis , 1998, Multiple sclerosis.

[24]  L. Peltonen,et al.  Immune system genes in multiple sclerosis: genetic association and linkage analyses on TCRβ, IGH, IFN-γ and IL-1ra/IL-1β loci , 1997, Journal of Neuroimmunology.

[25]  H. Kirchner,et al.  Correlation Between Interferon Production and Clinical Disease Activity in Patients with Multiple Sclerosis , 1997, Journal of Clinical Immunology.

[26]  M. Knip,et al.  Analysis of an Interferon-γ Gene (IFNG) Polymorphism in Danish and Finnish Insulin-Dependent Diabetes Mellitus (IDDM) Patients and Control Subjects , 1997 .

[27]  J. Haines,et al.  A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex , 1996, Nature Genetics.

[28]  T. Owens,et al.  Interferon‐γ confers resistance to experimental allergic encephalomyelitis , 1996, European journal of immunology.

[29]  A. Billiau.  Interferon- in Autoimmunity , 1996 .

[30]  E. Lander,et al.  A biometrical genome search in rats reveals the multigenic basis of blood pressure variation. , 1995, Genome research.

[31]  C. Brosnan,et al.  Cytokine localization in multiple sclerosis lesions , 1995, Neurology.

[32]  M. Cuzner,et al.  Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. , 1993, Cytokine.

[33]  A. Ruiz-Linares.  Dinucleotide repeat polymorphism in the interferon-gamma (IFNG) gene. , 1993, Human molecular genetics.

[34]  A. Billiau,et al.  Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. , 1988, Journal of immunology.

[35]  R. Hirsch,et al.  EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERON , 1987, The Lancet.

[36]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[37]  D. Goeddel,et al.  Structure of the human immune interferon gene , 1982, Nature.

[38]  Wheelock Ef.  Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. , 1965 .

[39]  M. Carrington,et al.  Polymorphisms of the human IFNG gene noncoding regions , 2000, Immunogenetics.

[40]  S. Pestka,et al.  Interferon receptors. , 1996, Biotherapy.